SCHEMBL11946291

SCHEMBL11946291

CC1(COc2c(N3CCN(S(=O)(=O)Cc4ccc5nc(-c6ccc(F)cc6)oc5c4)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ MAPT P10636 4/20 0.33
▸ UTRN P46939 3/20 0.33
▸ FASN P49327 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MGLL Q99685 1/20 0.32
▸ GPR119 Q8TDV5 5/20 0.31
▸ PARG Q86W56 1/20 0.30
▸ CYP17A1 P05093 1/20 0.30
▸ CYP21A2 P08686 1/20 0.30
▸ CYP11B1 P15538 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946289 0.95 GPR119 (0.32) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946294 0.90 MAPT (0.34) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946301 0.89 MAPT (0.33) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946297 0.88 MAPT (0.33) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946293 0.88 MAPT (0.34) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946296 0.87 MAPT (0.33) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946295 0.87 MAPT (0.32) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946292 0.86 MAPT (0.35) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL17057873 0.86 UTRN (0.32) MAPTUTRNFASNLMNATP53
SCHEMBL11946300 0.86 MAPT (0.33) POLBCYP3A4CYP2C19PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885CYP3A4 281/4885CYP2C19 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback